GLP-1 Drugs: Ohio Board of Pharmacy Issues FAQs for Compounders In spring 2025, the Food and Drug Administration (FDA) resolved and ended the GLP-1 medications shortage, subsequently releasing declaratory orders that neither outsourcing compounding pharmacies or pharmacies could compound drugs that were essentially copies of either semaglutide (available under the brand names Ozempic, Rybelsus, and Wegovy) and tirzepatide (available under the brand names Mounjaro, and Zepbound)
The most common side effects are mild nausea, occasional constipation, and reduced appetite, which is actually the intended effect
References Arias-Cordova, Y., Ble-Castillo, J
The goal is sending strong signals to your muscles that they remain necessary, even as calories decrease
In the first quarter, the company's revenue jumped by 19% year over year to $3.6 billion
Monitoring Requirements When Using Semaglutide with Anticoagulants Patients combining semaglutide with blood thinners need increased laboratory monitoring beyond standard GLP-1 therapy checkpoints
:max_bytes(150000):strip_icc()/DiabetesMentalHealth2-73d13703a7c3442ca4fce0a2e71f15b0.jpg)
